JP Morgan raises Halozyme price target to $78
JP Morgan increased its Halozyme Therapeutics price target to $78.00 per share from $70.00, according to ratings actions cited by Benzinga.
Story updates
09:15:40 PM UTC
SquawkNews
Halozyme Therapeutics Price Target Raised to $78.00/Share From $70.00 by JP Morgan